Options increase for CML patients failed by existing drugs
FDA approves ponatinib, third drug in four months; all clinical trials led by MD Anderson
MD Anderson News Release 12/21/12
The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved the drug ponatinib (Iclusig), which is effective in a...
Ibrutinib has 'unprecedented' impact on mantle cell lymphoma
Phase 2 clinical trial shows high overall response, remissions in patients with resistant disease
MD Anderson News Release...
Resolve to take Healthy Bites in 2013
UT MD Anderson experts launch cancer prevention nutrition challenge
MD Anderson News Release 12/13/12
Adults with...
MD Anderson researcher slated to lead Immunology Translational Research Dream Team
Stand Up to Cancer and the Cancer Research Institute fund joint effort for next generation cancer immunology research
MD Anderson News Release 12/12/12
Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) today announced the formation of a Dream Team project dedicated to cancer immunology to be led by James P. Allison, Ph.D., Chair of the Department of Immunology, Director of the Immunotherapy Platform...
Pre-transplant umbilical cord blood expansion in lab speeds establishment of new blood supply in patients, reducing high-risk time to recovery
Platelets, white blood cells engraft more quickly than in standard double-cord transplant
MD Anderson News Release 12/...
Weekly dose reduces targeted drug's side effects, but not its activity against acute lymphocytic leukemia
MD Anderson News Release 12/10/12
A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant...
Drug combination acts against aggressive chronic lymphocytic leukemia
Ibrutinib, rituximab deliver a one-two punch to patients with few good options
MD Anderson News Release 12/08/12
<...UT MD Anderson, GlaxoSmithKline to collaborate on new approach to cancer immune therapy; success could earn cancer center $335 million plus royalties
Deal to develop MD Anderson discovery draws on expertise of Institute for Applied Cancer Science
MD Anderson News Release...
UT MD Anderson study finds link between statins and improved survival in inflammatory breast cancer
Early results show benefit in most dangerous form of disease
MD Anderson News Release 12/06/12
Researchers from...
African American women with breast cancer less likely to have newer, recommended surgical procedure
Older technique associated with higher rate of lymphedema, poor outcome
MD Anderson News Release 12/05/12
African...